pharma& is a rapidly growing, internationally oriented company in a very exciting moment of expansion. In this section of the website, we regularly share our news with you.


pharma& Schweiz GmbH (“pharma&”) is proud to announce to have acquired all of the remaining rights of Farydak® (Panobinostat) from Secura Bio to secure long-term demand for a well-established therapy option used for the treatment of multiple myeloma.


We are proud to announce that we closed an agreement with Astellas Deutschland GmbH, (a subsidiary of Astellas Pharma Inc.) on December 31st 2021 to acquire Astellas’ worldwide rights* of Bendamustine commercialized under the brand names Levact®, Ribomustin® and others, securing access and continuous supply for patients benefitting from this well-established and distinguished therapy option.

​For any inquiries, please contact us at

*) excluding Marketing Authorizations in a small number of markets, including Morocco which is subject to merger clearance.

read more in our news archive